Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.

• Autores: Richard T. Owen
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 52, Nº. 1, 2016, págs. 29-40
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Suvorexant is a hypnotic representing the first-in-class of a new group of agents known as dual orexin receptor antagonists. They target cerebral orexin receptors which, when activated, contribute to arousal and wakefulness. Suvorexant was shown to decrease sleep onset times and increase sleep duration, whether assessed objectively by polysomnography or subjectively by sleep diaries in primary insomnia patients. Overall tolerability was good, with somnolence being the commonest adverse event (more than 7% in 3-month studies). No strong signals for rebound or withdrawal were seen after 1-12 months of treatment and few adverse events suggestive of residual psychomotor or cognitive events have been recorded. Further studies are required in patients with insomnia comorbid with depression and head-to-head studies with established hypnotics such as zolpidem and eszopiclone. Studies augmenting the small number of patients evaluating the initial recommended dose (10 mg) would also be prudent.